Merck's 9-valent HPV vaccine V503 under FDA review
This article was originally published in Scrip
Executive Summary
Merck revealed on 20 February that the FDA has accepted under a standard review the company's biologics license application for V503, an investigational 9-valent human papillomavirus (HPV) vaccine.